Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
about
Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach.The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cellsDelivery of DNAzyme targeting aurora kinase A to inhibit the proliferation and migration of human prostate cancer.Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.Quercetin suppresses lung cancer growth by targeting Aurora B kinase.Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitorA Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.The Effect of Aurora Kinase Inhibitor on Adhesion and Migration in Human Breast Cancer Cells and Clinical Implications.Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
P2860
Q28829011-53EE2010-EFEE-4034-8D69-A25AF1119625Q33167422-D498941D-7AF5-4079-87F5-7B4B3308BB5FQ33709521-8AE6DD7A-EA71-4E64-94B4-55B798F63220Q33835928-2EA2CAE6-9FAF-4C5B-8B77-DE3856CBB0BDQ34908239-34E59DD5-5D88-4F3F-8B6B-483931917159Q35194626-96572AE7-6AF5-41C7-AB33-E24567C4551CQ35794644-C6BCA6D0-BF4D-4A52-93D8-9EBCD209C02BQ36538710-F0BF4A22-9A5A-4237-ACBC-C5BA316FFE7AQ37013275-C130F6A7-D729-4E8B-9FDD-2BB4E1B9008EQ37429960-579742A9-1DED-4339-8D12-F1A5FAD921C2Q37699220-2AA233CA-60F5-43E7-9E50-624C41E54528Q38631566-077C9D10-DF47-4E8E-9373-8042AF4E872AQ38728487-09543353-1DB1-410D-AA8A-C46CCD7F3552Q38799626-6BBFF10E-5CC3-4AFD-A576-B5A64FD29A10Q38894287-C7C6AC87-CEE5-4A66-9783-74C6E821FEBFQ42430705-FDCA2A92-7ADE-4B43-9E9F-8305B3EF01C0Q46364752-727BDC80-E98D-48BE-881C-AA18BDF82BB3Q47339376-2AEDDA16-6820-4036-9060-0AB792CA2DFDQ49025576-C556ADA9-8A69-41C5-A860-9CC133464A8CQ55022875-16426C8E-7DA6-4B7A-B3D5-3F45035D2427
P2860
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
@en
type
label
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
@en
prefLabel
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
@en
P2093
P2860
P1476
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013)
@en
P2093
Jane Ying-Chieh Lee
Sailu Sarvagalla
Yi-Chun Huang
P2860
P304
P356
10.1517/13543776.2014.931374
P407
P577
2014-06-26T00:00:00Z